Royal United Hospitals Radiopharmacy Services Partnership Exploration

Royal United Hospitals NHS Foundation Trust is conducting soft market testing to explore partnership opportunities for expanding its Radiopharmacy Services in Southwest England. The Trust operates a state-of-the-art pharmacy facility on the M4/M5 corridor with specialized units for Cytotoxics (191 sq ft), Monoclonal Antibodies (180 sq ft), Radiopharmacy (279 sq ft), and available clean room space (108 sq ft). This soft market testing exercise seeks input from suppliers and investors on commercial, technical, and operational models for potential joint ventures or partnerships, including interest levels, available delivery models, risk mitigation strategies, service continuity options, and indicative timelines. This is an information-gathering exercise only and does not constitute a formal procurement process or competition. Responses will inform the Trust's future approach to potential procurement activity. Royal United Hospitals NHS Foundation Trust reserves the right not to proceed following this pre-engagement stage.